Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1989 Jun;83(6):1794–1799. doi: 10.1172/JCI114084

Acquired C1 inhibitor (C1-INH) deficiency type II. Replacement therapy with C1-INH and analysis of patients' C1-INH and anti-C1-INH autoantibodies.

J Alsenz 1, J D Lambris 1, K Bork 1, M Loos 1
PMCID: PMC303898  PMID: 2723058

Abstract

The response of two patients with autoantibody-mediated C1-inhibitor (C1-INH) deficiency to replacement therapy with C1-INH was studied over a period of 3 d. In patient 1 an acute attack of angioedema was successfully managed by infusion of 1,000 U of C1-INH concentrate. C1-INH function returned to normal levels within 30 min, while CH50 and C4 peaked after 6-7 h and C1 hemolytic activity reached 50-60% of normal after 3 d. Immediately after the injection an increase in C1-INH-anti-C1-INH complexes was observed. Based on NH2-terminal sequence analysis of the patients' Mr 96,000 C1-INH, it is concluded that this fragment is generated after cleavage of C1-INH in its active site by one of its target proteases without generating a covalent C1-INH-enzyme complex. In a second patient with a four to five times higher anti-C1-INH antibody titer, the infusion of 500 ml of plasma or of 2,000 U of C1-INH concentrate influenced neither the severity of the patient's angioedema nor the tested parameters, except for an increase in the amount of C1-INH-anti-C1-INH complexes. Analysis of patients' anti-C1-INH antibodies revealed that the antibodies recognize different epitopes within the C1-INH. This suggests that patients with acquired angioedema type II are a heterogenous group with respect to the C1-INH autoantibodies.

Full text

PDF
1794

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alsenz J., Bork K., Loos M. Autoantibody-mediated acquired deficiency of C1 inhibitor. N Engl J Med. 1987 May 28;316(22):1360–1366. doi: 10.1056/NEJM198705283162202. [DOI] [PubMed] [Google Scholar]
  2. Alsenz J., Loos M. A rapid and simple ELISA for the determination of duplicate monoclonal antibodies during epitope analysis of antigens and its application to the study of C1(-)-INH. J Immunol Methods. 1988 Apr 22;109(1):75–84. doi: 10.1016/0022-1759(88)90444-9. [DOI] [PubMed] [Google Scholar]
  3. Alsenz J., Loos M. Simplified methods for the purification, quantitation, and functional estimation of human complement C-1-inhibitor (C-1-INH) with a monoclonal anti-C-1-INH antibody. J Immunol Methods. 1987 Jan 26;96(1):107–114. doi: 10.1016/0022-1759(87)90373-5. [DOI] [PubMed] [Google Scholar]
  4. Bergamaschini L., Cicardi M., Tucci A., Gardinali M., Frangi D., Valle C., Agostoni A. C1 INH concentrate in the therapy of hereditary angioedema. Allergy. 1983 Feb;38(2):81–84. doi: 10.1111/j.1398-9995.1983.tb01590.x. [DOI] [PubMed] [Google Scholar]
  5. Bock S. C., Skriver K., Nielsen E., Thøgersen H. C., Wiman B., Donaldson V. H., Eddy R. L., Marrinan J., Radziejewska E., Huber R. Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization. Biochemistry. 1986 Jul 29;25(15):4292–4301. doi: 10.1021/bi00363a018. [DOI] [PubMed] [Google Scholar]
  6. Cicardi M., Bergamaschini L., Marasini B., Boccassini G., Tucci A., Agostoni A. Hereditary angioedema: an appraisal of 104 cases. Am J Med Sci. 1982 Jul-Aug;284(1):2–9. doi: 10.1097/00000441-198207000-00001. [DOI] [PubMed] [Google Scholar]
  7. Cicardi M., Frangi D., Bergamaschini L., Gardinali M., Sacchi G., Agostoni A. Acquired C1 inhibitor deficiency with angioedema symptoms in a patient infected with Echinococcus granulosus. Complement. 1985;2(2-3):133–139. doi: 10.1159/000467853. [DOI] [PubMed] [Google Scholar]
  8. Cicardi M., Igarashi T., Rosen F. S., Davis A. E., 3rd Molecular basis for the deficiency of complement 1 inhibitor in type I hereditary angioneurotic edema. J Clin Invest. 1987 Mar;79(3):698–702. doi: 10.1172/JCI112873. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cohen S. H., Koethe S. M., Kozin F., Rodey G., Arkins J. A., Fink J. N. Acquired angioedema associated with rectal carcinoma and its response to danazol therapy. Acquired angioedema treated with danazol. J Allergy Clin Immunol. 1978 Oct;62(4):217–221. doi: 10.1016/0091-6749(78)90210-5. [DOI] [PubMed] [Google Scholar]
  10. DONALDSON V. H., EVANS R. R. A BIOCHEMICAL ABNORMALITY IN HEREDIATRY ANGIONEUROTIC EDEMA: ABSENCE OF SERUM INHIBITOR OF C' 1-ESTERASE. Am J Med. 1963 Jul;35:37–44. doi: 10.1016/0002-9343(63)90162-1. [DOI] [PubMed] [Google Scholar]
  11. Doekes G., van Es L. A., Daha M. R. C1- inactivator: its efficiency as a regulator of classical complement pathway activation by soluble IgG aggregates. Immunology. 1983 Jun;49(2):215–222. [PMC free article] [PubMed] [Google Scholar]
  12. Donaldson V. H., Harrison R. A., Rosen F. S., Bing D. H., Kindness G., Canar J., Wagner C. J., Awad S. Variability in purified dysfunctional C1(-)-inhibitor proteins from patients with hereditary angioneurotic edema. Functional and analytical gel studies. J Clin Invest. 1985 Jan;75(1):124–132. doi: 10.1172/JCI111664. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Donaldson V. H., Wagner C. J., Tsuei B., Kindness G., Bing D. H., Harrison R. A., Rosen F. S. Interactions of plasma kallikrein and C1-s with normal and dysfunctional C1(-)-inhibitor proteins from patients with hereditary angioneurotic edema: analytic gel studies. Blood. 1987 Apr;69(4):1096–1101. [PubMed] [Google Scholar]
  14. Frank M. M. C1 esterase inhibitor: clinical clues to the pathophysiology of angioedema. J Allergy Clin Immunol. 1986 Nov;78(5 Pt 1):848–850. doi: 10.1016/0091-6749(86)90228-9. [DOI] [PubMed] [Google Scholar]
  15. Frank M. M., Gelfand J. A., Atkinson J. P. Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med. 1976 May;84(5):580–593. doi: 10.7326/0003-4819-84-5-580. [DOI] [PubMed] [Google Scholar]
  16. Gadek J. E., Hosea S. W., Gelfand J. A., Frank M. M. Response of variant hereditary angioedema phenotypes to danazol therapy. Genetic implications. J Clin Invest. 1979 Jul;64(1):280–286. doi: 10.1172/JCI109449. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Gadek J. E., Hosea S. W., Gelfand J. A., Santaella M., Wickerhauser M., Triantaphyllopoulos D. C., Frank M. M. Replacement therapy in hereditary angioedema: successful treatment of acute episodes of angioedema with partly purified C1 inhibitor. N Engl J Med. 1980 Mar 6;302(10):542–546. doi: 10.1056/NEJM198003063021002. [DOI] [PubMed] [Google Scholar]
  18. Geha R. S., Quinti I., Austen K. F., Cicardi M., Sheffer A., Rosen F. S. Acquired C1-inhibitor deficiency associated with antiidiotypic antibody to monoclonal immunoglobulins. N Engl J Med. 1985 Feb 28;312(9):534–540. doi: 10.1056/NEJM198502283120902. [DOI] [PubMed] [Google Scholar]
  19. Gelfand J. A., Boss G. R., Conley C. L., Reinhart R., Frank M. M. Acquired C1 esterase inhibitor deficiency and angioedema: a review. Medicine (Baltimore) 1979 Jul;58(4):321–328. doi: 10.1097/00005792-197907000-00004. [DOI] [PubMed] [Google Scholar]
  20. Hewick R. M., Hunkapiller M. W., Hood L. E., Dreyer W. J. A gas-liquid solid phase peptide and protein sequenator. J Biol Chem. 1981 Aug 10;256(15):7990–7997. [PubMed] [Google Scholar]
  21. Jackson J., Sim R. B., Whelan A., Feighery C. An IgG autoantibody which inactivates C1-inhibitor. Nature. 1986 Oct 23;323(6090):722–724. doi: 10.1038/323722a0. [DOI] [PubMed] [Google Scholar]
  22. Kleinhans D., Schach A., Rüther U., Jipp P. Immunozytom mit erworbenem C1-Esterase-Inhibitor-Mangel und rezidivierendem Angioödem. Dtsch Med Wochenschr. 1986 May 9;111(19):742–744. doi: 10.1055/s-2008-1068524. [DOI] [PubMed] [Google Scholar]
  23. Malbran A., Hammer C. H., Frank M. M., Fries L. F. Acquired angioedema: observations on the mechanism of action of autoantibodies directed against C1 esterase inhibitor. J Allergy Clin Immunol. 1988 Jun;81(6):1199–1204. doi: 10.1016/0091-6749(88)90891-3. [DOI] [PubMed] [Google Scholar]
  24. ROSEN F. S., PENSKY J., DONALDSON V., CHARACHE P. HEREDITARY ANGIONEUROTIC EDEMA: TWO GENETIC VARIANTS. Science. 1965 May 14;148(3672):957–958. doi: 10.1126/science.148.3672.957. [DOI] [PubMed] [Google Scholar]
  25. Rosen F. S., Alper C. A., Pensky J., Klemperer M. R., Donaldson V. H. Genetically determined heterogeneity of the C1 esterase inhibitor in patients with hereditary angioneurotic edema. J Clin Invest. 1971 Oct;50(10):2143–2149. doi: 10.1172/JCI106708. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Salvesen G. S., Catanese J. J., Kress L. F., Travis J. Primary structure of the reactive site of human C1-inhibitor. J Biol Chem. 1985 Feb 25;260(4):2432–2436. [PubMed] [Google Scholar]
  27. Schapira M., de Agostini A., Schifferli J. A., Colman R. W. Biochemistry and pathophysiology of human C1 inhibitor: current issues. Complement. 1985;2(2-3):111–126. doi: 10.1159/000467851. [DOI] [PubMed] [Google Scholar]
  28. Sheffer A. L., Austen K. F., Rosen F. S., Fearon D. T. Acquired deficiency of the inhibitor of the first component of complement: report of five additional cases with commentary on the syndrome. J Allergy Clin Immunol. 1985 Jun;75(6):640–646. doi: 10.1016/0091-6749(85)90087-9. [DOI] [PubMed] [Google Scholar]
  29. Späth P. J., Wüthrich B., Bütler R. Quantification of C1-inhibitor functional activities by immunodiffusion assay in plasma of patients with hereditary angioedema--evidence of a functionally critical level of C1-inhibitor concentration. Complement. 1984;1(3):147–159. doi: 10.1159/000467830. [DOI] [PubMed] [Google Scholar]
  30. Ziccardi R. J. A new role for C-1-inhibitor in homeostasis: control of activation of the first component of human complement. J Immunol. 1982 Jun;128(6):2505–2508. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES